Laurus Labs share price
NSE: LAURUSLABSBSE: 540222Pharmaceuticals & BiotechnologyMid Cap
Laurus Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2016 · Issue price ₹428
Last close ₹2,142.00up ₹83.10 (4.04%)BSE ₹2,139.80
Share price at the NSE close on 27 Oct 2026. Previous close ₹2,058.90.
27 Oct: open ₹2,075.00, high ₹2,143.10, low ₹2,067.40
52-week range of traded prices to 27 Oct 2026
₹917.95Low, 2 Feb 2026₹2,143.10High, 27 Oct 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,15,735 Cr171st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 105.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 21.84
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.09%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 22.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.44
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 31,17,05747.5% delivered
About Laurus Labs
Laurus Labs Limited is a pharmaceutical and biotechnology company.1 It makes active pharmaceutical ingredients (APIs, the active substance in a medicine) and finished medicines, and develops and manufactures new drugs under contract for innovator drug companies.2 Its customers are drug makers, generic companies and institutional buyers around the world, and its main manufacturing base is Visakhapatnam.34
The business runs as 2 divisions.5 Affordable Medicines makes APIs, such as antiretroviral (HIV), oncology and cardiovascular drugs, for generic companies, and finished medicines taken by mouth.6 CDMO (contract development and manufacturing) makes small-molecule drugs for innovators from early development to commercial supply, and its Bio arm offers precision fermentation (making ingredients with engineered microbes).76
It was incorporated in 2005 and began as an API maker before adding finished medicines.89 It serves more than 275 clients, including 7 big pharmaceutical companies.10 In the year to Mar 2026, customers outside India brought in ₹4,569.13 crore of consolidated revenue and customers in India ₹2,243.77 crore.11 Besides Visakhapatnam, it has fermentation sites in Bengaluru and development facilities in Hyderabad.4
As of 31 Mar 2026, it owned 78.34% of Laurus Bio and 49% of KRKA Pharma, a joint venture with KRKA d.d. of Slovenia; its associate ImmunoACT develops and makes CAR-T cell therapy (a cancer treatment made from a patient's own immune cells) in Mumbai.121314 Its promoters include Satyanarayana Chava, the chief executive, and V V Ravi Kumar, the chief financial officer; Chava's son Krishna Chaitanya Chava and daughter Soumya Chava are executive directors.1516
Laurus Labs key points
Results
- In the quarter to Jun 2026, revenue rose 29% to ₹2,026 crore, EBITDA (profit before interest, tax, depreciation and amortisation) was ₹644 crore at a 31.8% margin, and net profit rose 126% to ₹368 crore. Each was the company's highest for a quarter.171819
- In the year to Mar 2026, consolidated revenue rose 23% to ₹6,813 crore, EBITDA 64% to ₹1,826 crore at a 26.8% margin, and net profit 148% to ₹889 crore.2021
- Net debt (borrowings less cash) was ₹2,656 crore at the end of June 2026, about 1.28 times EBITDA, against 1.25 a quarter earlier.22
Business segments
- In the year to Mar 2026, CDMO revenue rose 36% to ₹2,080 crore, 31% of the total, and Affordable Medicines 18% to ₹4,733 crore.23
- Revenue by business, and growth242526
Item year to Mar 2026 Small-molecule CDMO ₹1,896 crore, up 38% Bio CDMO ₹184 crore, up 15% APIs ₹2,746 crore, up 13% Finished medicines (FDF) ₹1,987 crore, up 26% - In the quarter to Jun 2026, small-molecule CDMO sales rose 69% to ₹835 crore, Bio sales about 21% to about ₹35 crore, and Affordable Medicines 10% to ₹1,156 crore.27
- At the end of March 2026, the small-molecule CDMO pipeline had more than 125 active projects, over 102 in human health and around 23 in animal health and crop science.7
Revenue mix
- Antiretroviral (HIV) medicines, APIs and finished doses together, brought in ₹2,807 crore in the year to Mar 2026, up 10% from ₹2,559 crore.28
- About 55% of small-molecule CDMO revenue in the quarter to Jun 2026 came from commercial supplies (for approved medicines).29
- CDMO work is for innovators' on-patent molecules; contract manufacturing of off-patent molecules is counted in Affordable Medicines.30
Plants and capacity
- It has 15 manufacturing sites, with 8,800 kilolitres (kL) of API capacity (reactor volume for active ingredients), capacity for 12 billion finished-dose units and 240 kL of fermentation capacity.31
- In its presentation of 18 Sep 2026, the company listed Unit 10 and a 400 kL fermentation plant in Visakhapatnam, and the KRKA joint venture's Hyderabad plant, as new sites under expansion or construction.32
Research and development
- Consolidated R&D spending was ₹282 crore, 4% of revenue, in the year to Mar 2026, and ₹118 crore, 5.8%, in the quarter to Jun 2026, including ₹35 crore of capital R&D on gene therapy and antibody-drug conjugates (antibodies carrying a drug to cancer cells).3334
- It has 1,570 research scientists and has filed 92 drug master files (files on how an API is made) and 96 finished-medicine dossiers in the US, Europe and Canada.3135
- It has in-licensed 2 antibody-drug conjugates from Aarvik Therapeutics to develop and sell in India.36
Expansion and capital spending
- Capital spending was ₹1,070 crore in the year to Mar 2026, 16% of revenue.4
- In its presentation of 18 Sep 2026, the company said it plans capital spending of more than ₹3,000 crore over the year to Mar 2027 and the following year.37
- The company stated in its annual report for the year to Mar 2026 that its Unit 7 site is expected to start commercial validation production by March 2027, with 4 more units in the year to Mar 2028.38
- The company stated in its annual report for the year to Mar 2026 that Andhra Pradesh allotted it 531.77 acres for a Laurus Pharma Zone, projecting ₹5,630 crore of investment over 8 years. On 24 Jul 2026, it said handover was in its final stages.3940
What the company expects
- In its presentation of 18 Sep 2026, the company said it guides to an EBITDA margin above 30% from the year to Mar 2027.41
- On its earnings call of 24 Jul 2026, the company said it expects at least 50% of revenue to come from CDMO by the year to Mar 2030.42
- On its earnings call of 24 Jul 2026, the company said about 1/3 of revenue comes from antiretroviral medicines and expects that share to go down.29
- In its presentation of 18 Sep 2026, the company said the first phase of the KRKA joint venture's formulation plant is to open in mid-2027, for high-potency and general oral doses.35
Recent events
- In its exchange filing of 14 Oct 2026, the company said it had invested further in KRKA Pharma through a rights issue (new shares offered to existing shareholders), with its stake unchanged.43
- On 24 Jul 2026, the National Company Law Tribunal listed for 10 Sep 2026 the hearing on merging subsidiary Laurus Synthesis, except its Unit-1, into the company; the company's documents give no outcome.44
- On 3 Jul 2026, the company received CARE Ratings' letter reaffirming its credit rating (a view of its ability to repay debt) on long-term bank facilities at CARE AA; Stable.45
Last updated
All 45 sources, each with its page
- 1. Annual report, 8 Jun 2026, page 8
- 2. Annual report, 8 Jun 2026, page 53
- 3. Annual report, 8 Jun 2026, page 82
- 4. Annual report, 8 Jun 2026, page 18
- 5. Investor presentation, 18 Sep 2026, page 6
- 6. Annual report, 8 Jun 2026, page 54
- 7. Annual report, 8 Jun 2026, page 16
- 8. Annual report, 8 Jun 2026, page 81
- 9. Annual report, 8 Jun 2026, page 5
- 10. Annual report, 8 Jun 2026, page 38
- 11. Annual report, 8 Jun 2026, page 162
- 12. Annual report, 8 Jun 2026, page 142
- 13. Annual report, 8 Jun 2026, page 58
- 14. Annual report, 8 Jun 2026, page 19
- 15. Annual report, 8 Jun 2026, page 69
- 16. Annual report, 8 Jun 2026, page 182
- 17. Investor presentation, 18 Sep 2026, page 20
- 18. Investor presentation, 18 Sep 2026, page 21
- 19. Earnings call, 24 Jul 2026, page 3
- 20. Annual report, 8 Jun 2026, page 56
- 21. Annual report, 8 Jun 2026, page 12
- 22. Earnings call, 24 Jul 2026, page 6
- 23. Annual report, 8 Jun 2026, page 43
- 24. Annual report, 8 Jun 2026, page 54
- 25. Annual report, 8 Jun 2026, page 14
- 26. Annual report, 8 Jun 2026, page 15
- 27. Earnings call, 24 Jul 2026, page 4
- 28. Annual report, 8 Jun 2026, page 54
- 29. Earnings call, 24 Jul 2026, page 7
- 30. Earnings call, 24 Jul 2026, page 14
- 31. Investor presentation, 18 Sep 2026, page 7
- 32. Investor presentation, 18 Sep 2026, page 7
- 33. Annual report, 8 Jun 2026, page 20
- 34. Investor presentation, 18 Sep 2026, page 21
- 35. Investor presentation, 18 Sep 2026, page 15
- 36. Investor presentation, 18 Sep 2026, page 16
- 37. Investor presentation, 18 Sep 2026, page 8
- 38. Annual report, 8 Jun 2026, page 55
- 39. Annual report, 8 Jun 2026, page 57
- 40. Earnings call, 24 Jul 2026, page 4
- 41. Investor presentation, 18 Sep 2026, page 4
- 42. Earnings call, 24 Jul 2026, page 11
- 43. Exchange filing, 14 Oct 2026, page 1
- 44. Exchange filing, 25 Jul 2026, page 1
- 45. Exchange filing, 3 Jul 2026, page 1
Results
Consolidated; ₹ crore.Laurus Labs quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +22.6%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +114.9%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,026 Crup 11.85%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹362 Crup 28.35%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 17.9%
Revenue by quarter
Peak revenue ₹2,026 Cr, quarter to Jun 2026; lowest ₹1,224 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,224 | 1,415 | 1,720 | 1,570 | 1,653 | 1,778 | 1,812 | 2,026 |
| Net profit | 20 | 93 | 233 | 162 | 194 | 252 | 282 | 362 |
| Net margin | 1.6% | 6.6% | 13.5% | 10.3% | 11.8% | 14.2% | 15.6% | 17.9% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹6,813 Crup 22.67%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹890 Crup 148.41%
- Net margin
- 13.1%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,932what Revenue, Mar 2017, includes. This period's revenue includes excise duty of ₹27 crore, a tax on the goods the company makes that it collects and pays to the government. | 2,069what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹13 crore, a tax on the goods the company makes that it collects and pays to the government. | 2,292 | 2,832 | 4,814 | 4,936 | 6,041 | 5,041 | 5,554 | 6,813 |
| Net profit | 190 | 168 | 94 | 255 | 984 | 832 | 793 | 162 | 358 | 890 |
| Net margin | 9.9% | 8.1% | 4.1% | 9.0% | 20.4% | 16.9% | 13.1% | 3.2% | 6.5% | 13.1% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacturer of Generics API, Generics FDF, Synthesis and Bio Technology, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.Laurus Labs PE ratio and valuation
Price to earnings
At or below today's level on 85% of 2,207 trading days since Nov 2017.
LowestHighest
Its median35.90Industry median28.32
Price to book
At or below today's level on 100% of 1,978 trading days since Nov 2018.
LowestHighest
Its median7.08Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 5% of 2,425 trading days since Jan 2017.
LowestHighest
Its median0.33%Industry median0.50%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +62.0% | +147.7% | −34.7% | 0.2% |
| 3 years | +50.4% | +3.9% | +44.6% | 0.2% |
| 5 years | +22.7% | −2.1% | +25.0% | 0.3% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
219 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 133 of the 168 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 219 funds holding Laurus Labs
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 13
- AddedAdded. Funds that held more shares than at the end of the month before.
- 89
- CutCut. Funds that held fewer shares than at the end of the month before.
- 79
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 34
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 3
| Fund | |||
|---|---|---|---|
 Mirae Asset Large & Midcap FundMirae Asset Mutual Fund | 88,66,688 | 4.10% | ₹1,755.6 Cr |
| Mirae Asset ELSS Tax Saver FundMirae Asset Mutual Fund | 56,58,404 | 4.55% | ₹1,120.4 Cr |
| Mirae Asset Midcap FundMirae Asset Mutual Fund | 42,53,201 | 4.31% | ₹842.1 Cr |
 UTI Nifty 200 Momentum 30 Index FundUTI Mutual Fund | 26,29,596 | 6.54% | ₹520.7 Cr |
 HSBC Small Cap FundHSBC Mutual Fund | 12,82,134 | 1.37% | ₹253.9 Cr |
 SBI Healthcare Opportunities FundSBI Mutual Fund | 12,00,000 | 4.05% | ₹237.6 Cr |
| Mirae Asset Aggressive Hybrid FundMirae Asset Mutual Fund | 9,89,827 | 2.12% | ₹196.0 Cr |
| Mirae Asset Healthcare FundMirae Asset Mutual Fund | 9,72,748 | 5.51% | ₹192.6 Cr |
 Axis Small Cap FundAxis Mutual Fund | 9,00,000 | 0.58% | ₹178.2 Cr |
 WhiteOak Capital Mid Cap FundWhiteOak Capital Mutual Fund | 8,36,111 | 2.20% | ₹165.6 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Laurus Labs insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 3 pledge filings of unclear kind
- Others: no market trade · 62 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Laurus Labs competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Laurus Labs in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA | 4,20,172 | 34.74 | 5.03 | +11.4% | +16.6% | 15.5% | 16.9% | 0.91% |
 Divi's LaboratoriesDIVISLAB | 2,52,341 | 86.27 | 15.06 | +16.3% | +26.8% | 18.4% | 20.8% | 0.32% |
 Torrent PharmaceuticalsTORNTPHARM | 1,75,920 | 82.82 | 9.57 | +42.1% | −0.7% | 15.8% | 12.0% | 0.82% |
 Zydus LifesciencesZYDUSLIFE | 1,16,997 | 25.92 | 4.32 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,09,343 | 39.05 | 2.82 | −3.5% | −51.5% | 7.5% | 6.0% | 0.61% |
 CiplaCIPLA | 1,09,063 | 37.65 | 3.08 | −0.7% | −46.8% | 8.5% | 9.7% | 0.96% |
 Mankind PharmaMANKIND | 1,03,365 | 45.97 | 5.88 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 93,643 | 25.22 | 2.47 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Laurus Labs dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹2.00 a share, in 4 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 8 May 2026 | Interim | ₹1.20 |
| 31 Oct 2025 | Interim | ₹0.80 |
| 9 May 2025 | Interim | ₹0.80 |
| 6 Nov 2024 | Interim | ₹0.40 |
| 8 May 2024 | Interim | ₹0.40 |
| 2 Nov 2023 | Interim | ₹0.40 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Laurus Labs announcements
Oct 2026
14 Oct · General Updates
14 Oct · General Updates
13 Oct · Analysts
6 Oct · General Updates
Sep 2026
15 Sep · Analysts
Laurus Labs share price by year
Each calendar year to 2025.Laurus Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,108.00 | +83.8% | 1,108.00 | 510.75 |
| 2024 | 602.70 | +40.1% | 602.70 | 370.30 |
| 2023 | 430.20 | +14.6% | 435.45 | 289.75 |
| 2022 | 375.25 | −30.4% | 611.05 | 372.80 |
| 2021 | 538.90 | +52.6% | 708.70 | 341.70 |
| 2020 | 353.15 | +390.8% | 353.75 | 63.19 |
| 2019 | 71.95 | −5.2% | 81.06 | 62.05 |
| 2018 | 75.91 | −30.1% | 112.20 | 68.04 |
| 2017 | 108.58 | +12.9% | 125.68 | 94.55 |
| 2016 | 96.17 | – | 97.25 | 91.04 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2016 is from its first session, 19 Dec 2016.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 1,960.00 | 2,058.90 | 1,951.60 | 2,058.90 | 2,017.56 | 18,58,328 | 45.1% |
| 23 Oct 2026 | 1,987.50 | 2,009.60 | 1,933.50 | 1,970.00 | 1,958.52 | 18,93,713 | 45.3% |
| 22 Oct 2026 | 1,993.50 | 2,019.80 | 1,956.60 | 2,002.50 | 1,996.59 | 15,38,717 | 41.1% |
| 21 Oct 2026 | 2,052.90 | 2,079.80 | 1,993.40 | 2,012.50 | 2,026.31 | 12,75,844 | 46.8% |
| 19 Oct 2026 | 2,060.10 | 2,089.00 | 2,052.20 | 2,069.00 | 2,068.84 | 11,33,053 | 42.8% |
| 16 Oct 2026 | 2,030.40 | 2,086.00 | 2,028.70 | 2,060.10 | 2,062.54 | 16,06,547 | 50.6% |
| 15 Oct 2026 | 2,025.00 | 2,046.30 | 2,008.00 | 2,018.50 | 2,026.98 | 8,58,713 | 51.2% |
| 14 Oct 2026 | 2,049.00 | 2,057.30 | 2,019.20 | 2,036.90 | 2,036.68 | 13,01,046 | 51.0% |
| 13 Oct 2026 | 2,047.10 | 2,065.00 | 2,007.80 | 2,059.40 | 2,036.15 | 11,41,354 | 41.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 29 Sep 2020 | Split | 0.2000 | Each share became 5. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- LAURUSLABS
- BSE code
- 540222
- ISIN
- INE947Q01028
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.lauruslabs.com
- CIN
- L24239AP2005PLC047518
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2005
- Registered office
- Plot No.21, Jawaharlal Nehru Pharma City, Parawada, Visakapatnam 531021, Andhra Pradesh
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, Nifty Midcap 100